Posted by Trevor Kearing on Jan 19th, 2026
Shares of Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven analysts that are currently covering the company, MarketBeat Ratings reports. One...
More of this article »